April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Combination Bevacizumab and Grid Pattern Focal Laser Using a Minimum of 900 Sub-Threshold Spots For Diabetic Macular Edema
Author Affiliations & Notes
  • Marc T. Mathias
    Ophthalmology, University of Colorado Hospital, Aurora, Colorado
  • Hugo Quiroz-Mercado
    Ophthalmology, Denver Health Medical Center, Denver, Colorado
  • Raul Velez-Montoya
    Retina Department, Asoc para Evitar la Ceguera en Mex, Mexico, Mexico
  • Naresh Mandava
    Rocky Mountain Lions Eye Inst, Aurora, Colorado
  • Scott C. Oliver
    Ophthalmology, Univ of Colorado Health Sci Ctr, Aurora, Colorado
  • Jeffrey Olson
    Ophthalmology, University of Colorado, Aurora, Colorado
  • Footnotes
    Commercial Relationships  Marc T. Mathias, None; Hugo Quiroz-Mercado, Optimedica Consultant (C); Raul Velez-Montoya, None; Naresh Mandava, None; Scott C. Oliver, None; Jeffrey Olson, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 587. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marc T. Mathias, Hugo Quiroz-Mercado, Raul Velez-Montoya, Naresh Mandava, Scott C. Oliver, Jeffrey Olson; Combination Bevacizumab and Grid Pattern Focal Laser Using a Minimum of 900 Sub-Threshold Spots For Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2011;52(14):587.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate patients with diabetic macular edema (DME) treated with combination intravitreal bevacizumab and single grid pattern focal laser using a minimum of 900 sub-threshold spots.

Methods: : A retrospective chart review of patients undergoing combination bevacizumab and sub-threshold single grid pattern macular laser for DME was performed. Inclusion criteria included all patients with DME treated with single-session focal laser using a minimum of 900 sub-threshold spots in combination with intravitreal bevacizumab within 6 weeks. All patients had good quality pre and post-treatment macular thickness imaging by Ocular Coherence Tomography (OCT) and a minimum of 2 months follow-up. Sixteen (n=16) eyes of fourteen patients met the inclusion criteria. Sub-threshold treatment was defined as laser spots with a mild gray or lighter color. The Pascal laser was used for all grid pattern laser and parameters ranged from 100 to 150 mW power, 10 to 20 ms duration, and 100 micron spot size. Outcome measures were change in visual acuity and change in macular thickness as measured by OCT. Macular thickness maps were divided into 9 retinal sectors and pre and post-treatment thicknesses were compared in all 9 sectors. Pre and post-treatment Snellen visual acuities were converted to numerical decimal values to allow for statistical analysis. Statistical analysis of visual acuity and macular thickness was performed using the Wilcoxon matched-pairs test.

Results: : Mean pre-treatment visual acuity was 0.30+/-0.08 and mean post-treatment visual acuity was 0.4+/-0.08 with a p-value of 0.064. Statistically significant (p<0.05) reduction in macular thickness was observed in 7 of 9 retinal sectors.

Conclusions: : In a small cohort of 16 eyes with DME, combination intravitreal bevacizumab and single-session grid pattern macular laser using a minimum of 900 sub-threshold spots demonstrated statistically significant improvement in macular thickness in 7 of 9 retinal sectors. A trend towards improvement in visual acuity was observed although this was not statistically significant (p=0.64). We propose that combination sub-threshold grid pattern laser using a minimum of 900 spots and intravitreal bevacizumab is effective in the treatment of DME.

Keywords: diabetes • retina • laser 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.